Cardiometabolic risk
The combined risk to the heart and metabolism, elevated in PMOS even in younger women. A reason to address metabolic health early, not later.
Cardiometabolic risk is the combined likelihood of conditions affecting the heart, blood vessels, and metabolism, including type 2 diabetes, high blood pressure, unfavourable cholesterol patterns, and cardiovascular events.
In PMOS, this risk is elevated, and the 2026 Lancet consensus moved it to the centre of how the condition is understood. The elevation is present even in pre-menopausal women, which matters because younger women are often told they are too young to think about heart health.
The point of naming this is not alarm. It is timing. The same interventions that improve insulin sensitivity (sleep, meal composition, resistance training, and where appropriate medication) also lower cardiometabolic risk. Addressing the metabolic core of PMOS early is the most direct way to act on this risk, which is why screening for it is part of current PMOS care.